Werewolf Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Jul 31, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 31, 2026
HOWL$0.97-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations for the and
Condensed Consolidated Statements of Operations (unaudited)
(amounts in thousands, except share and per share amounts)
| Three Months EndedJune 30, | Six Months EndedJune 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Revenue: | ||||
| Collaboration revenue | $21,000 | $— | $21,000 | $— |
| Operating expenses: | ||||
| Research and development | 6,162 | 13,143 | 14,343 | 26,263 |
| General and administrative | 7,680 | 4,399 | 12,770 | 9,270 |
| Total operating expenses | 13,842 | 17,542 | 27,113 | 35,533 |
| Operating income (loss) | 7,158 | (17,542) | (6,113) | (35,533) |
| Other expense: | ||||
| Interest income | 277 | 850 | 710 | 1,847 |
| Interest expense | (475) | (1,301) | (1,843) | (2,564) |
| Loss on extinguishment of note payable | (3,354) | — | (3,354) | — |
| Other income, net | 64 | 11 | 738 | 179 |
| Total other expense | (3,488) | (440) | (3,749) | (538) |
| Net income (loss) | $3,670 | $(17,982) | $(9,862) | $(36,071) |
| Net income (loss) per common share, basic and diluted | $0.08 | $(0.40) | $(0.20) | $(0.80) |
| Weighted-average common shares outstanding, basic and diluted | 48,597,534 | 44,981,746 | 48,597,177 | 44,904,880 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.